This study provides a systematic framework for the clinical classification and personalized treatment of Castleman disease, offering significant guidance for iMCD-TAFRO and experimental designs related to the IL-6 signaling pathway.
Literature Overview
The article 'Overview of Castleman disease,' published in the journal Blood, systematically explores the heterogeneity, pathophysiological mechanisms, and treatment advances of Castleman disease (CD). It reviews the clinical and pathological evolution since Benjamin Castleman first described the condition in 1954, further integrating classification systems for HHV8, POEMS, and idiopathic multicentric CD (iMCD). In recent years, deeper insights into IL-6, VEGF, and T-cell signaling pathways have clarified the molecular mechanisms of CD, laying a theoretical foundation for targeted therapies. The research team emphasizes the value of natural history registries (e.g., ACCELERATE) in advancing rare disease research and advocates for multidisciplinary collaboration and patient engagement.Background Knowledge
1. The core challenge addressed by this study is the extreme heterogeneity of Castleman disease: CD is not a single entity but encompasses at least four distinct clinicopathological syndromes—UCD, HHV8-MCD, POEMS-MCD, and iMCD—with markedly different clinical manifestations, treatment responses, and prognoses, often misdiagnosed as lymphoma or autoimmune disorders. 2. The current bottleneck in IL-6 research lies in the fact that although IL-6 has been established as a key driver in iMCD and drugs like siltuximab and tocilizumab are effective, nearly half of patients do not respond to IL-6 inhibition, suggesting involvement of alternative cytokines or signaling pathways (e.g., mTOR), which remain incompletely understood. 3. The research focus stems from a systematic classification and consensus diagnostic criteria (e.g., distinguishing iMCD-TAFRO from iMCD-NOS), integrating molecular pathology with clinical phenotypes to enable precise subtyping and individualized treatment. The study particularly investigates the roles of plasma cells, follicular dendritic cells (FDC), and endothelial cells across subtypes, guiding future animal model development and targeted interventions.
Research Methods and Experiments
The authors systematically reviewed the classification and diagnostic criteria of CD based on extensive retrospective studies, prospective cohort data, and pathological consensus. The study integrated clinical data from the CDCN, employing histopathological analysis (e.g., HV vs. PC subtypes) and molecular testing (e.g., HHV8-LANA1, IL-6 levels) for subtyping. In mechanistic investigations, next-generation sequencing revealed enrichment of PDGFRB mutations in UCD, suggesting a possible clonal neoplastic origin. Additionally, the research team used RNA hybridization capture sequencing to screen for unknown viruses, ruling out infections beyond HHV8 as causative agents in iMCD, supporting hypotheses of autoimmune or clonal immune dysregulation.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a systematic framework for the precise diagnosis and treatment of Castleman disease, advancing the shift from 'symptom control' to 'mechanism-guided' therapy. For drug development, clearly defined targets such as IL-6, VEGF, and mTOR offer directions for novel therapeutics, especially for refractory iMCD patients. In clinical monitoring, routine testing for HHV8, HIV, and M-protein is recommended to differentiate subtypes and guide treatment. Moreover, establishing natural history registries (e.g., ACCELERATE) facilitates long-term follow-up and biomarker discovery.
Conclusion
Castleman disease, as a rare and highly heterogeneous systemic lymphoproliferative disorder, depends on multidisciplinary collaboration and patient engagement for research progress. This article systematically summarizes the classification, pathogenic mechanisms, and treatment strategies of CD, emphasizing the importance of precise subtyping. From bench to bedside, this study provides a theoretical basis for individualized treatment of iMCD, HHV8-MCD, and POEMS-MCD. Future research should focus on elucidating the molecular mechanisms of non-IL-6-driven iMCD, exploring interactions between T cells and plasma cells, and developing novel targeted therapies. Furthermore, utilizing animal models to simulate pathological processes of different subtypes will help validate therapeutic targets and accelerate drug translation. This study not only offers a comprehensive review of CD but also sets a paradigm for rare disease research, potentially enhancing the standardization and accessibility of global Castleman disease care systems.
